Table 2.
Virologic response
| Variable | N (%) | Group I N (%) | Group II N (%) | P value |
|---|---|---|---|---|
| Virologic response ЕVR | ||||
| Yes | 45(93.75) | 22 (95.65) | 23 (92) | Fisher exact, p = 1.0 |
| No | (36.25) | 1 (4.35) | 2 (8) | |
| Virologic response ЕTR | ||||
| Yes | 53(85.48) | 25 (89.29) | 28 (82.35) | Fisher exact, p = 0.49 |
| No | 9(14.52) | 3 (10.71) | 6 (17.65) | |
| Virologic response SVR | ||||
| Yes | 56(80) | 30 (85.71) | 26 (74.29) | P = 0.23 |
| No | 14(20) | 5 (14.29) | 9 (25.71) | |
Group I (with Atorvastatin), group II (without Atorvastatin); p (Chi-square test): EVR (early virologic response-12 week of the beginning of therapy); ETR (end of virologic treatment response); SVR (sustained virologic response – 6 months after the end of treatment).